Hudson Bay Capital Management
CARM

Hudson Bay Capital Management’s Carisma Therapeutics CARM Stock Holding History

Hudson Bay Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-65,318
Closed -$1.96M – 414
2019
Q2 		$1.96M Buy
+65,318
New +$1.96M 0.05% 276

Other funds holding CARM

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hudson Bay Capital Management's CARM Position: Q3 2019 in Review

Hudson Bay Capital Management sold out of Carisma Therapeutics (CARM) in Q3 2019, closing a stake of 65,318 shares — an estimated $1.96M sold.

Hudson Bay Capital Management first reported a position in CARM in Q2 2019 and held it in 1 quarter. The position peaked at $1.96M in Q2 2019. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2019.

  • Hudson Bay Capital Management reported no remaining Carisma Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Hudson Bay Capital Management sold 65,318 Carisma Therapeutics shares in Q3 2019, an estimated $1.96M.
  • Hudson Bay Capital Management first reported a position in Carisma Therapeutics in Q2 2019 and held it in 1 quarter.
  • Hudson Bay Capital Management's Carisma Therapeutics position peaked at $1.96M in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2019.

Based on Hudson Bay Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.